Zentalis Pharmaceuticals (NASDAQ:ZNTL) Issues Quarterly Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL) released its earnings results on Wednesday. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09, Zacks reports. The business had revenue of $26.90 million for the quarter.

Zentalis Pharmaceuticals Stock Up 1.7 %

ZNTL stock traded up $0.03 during midday trading on Thursday, hitting $1.79. The company’s stock had a trading volume of 1,010,820 shares, compared to its average volume of 1,806,906. The firm has a 50-day simple moving average of $2.06 and a 200-day simple moving average of $2.87. The firm has a market capitalization of $127.56 million, a P/E ratio of -0.72 and a beta of 1.75. Zentalis Pharmaceuticals has a 52-week low of $1.61 and a 52-week high of $16.27.

Insider Transactions at Zentalis Pharmaceuticals

In related news, Director Jan Skvarka acquired 60,000 shares of the stock in a transaction dated Friday, January 31st. The stock was acquired at an average cost of $1.72 per share, with a total value of $103,200.00. Following the completion of the transaction, the director now owns 149,551 shares in the company, valued at $257,227.72. This represents a 67.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Ingmar Bruns bought 20,000 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The shares were purchased at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the completion of the purchase, the insider now directly owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. This trade represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Analysts Set New Price Targets

ZNTL has been the topic of a number of recent research reports. Wells Fargo & Company lowered their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday. UBS Group cut their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Finally, Wedbush reissued a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $8.24.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.